Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Chemours CoCC · Entity 4420 | SVP, CFO | March 01, 2023 | March 10, 2023 |
| Veralto CorpVLTO · Entity 3203 | SVP, Chief Financial Officer | July 15, 2026 | July 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Chemours Co
Report date March 01, 2023 · Filed March 10, 2023 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.32 · Expires 2023-03-01 | Direct | 28,807 |
Reported balance
After 2023-03-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 28,807 · Balance 28,807 F1: Represents a 10 percent premium above the closing price of the Company common stock on the date of grant F2: The original Form 4, filed on March 3, 2023, is amended by this Form 4 amendment solely to revise the number of performance stock options received by the reporting person. F3: These options are scheduled to vest in three equal annual installments beginning on March 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a 10 percent premium above the closing price of the Company common stock on the date of grant
F2: The original Form 4, filed on March 3, 2023, is amended by this Form 4 amendment solely to revise the number of performance stock options received by the reporting person.
F3: These options are scheduled to vest in three equal annual installments beginning on March 1, 2024.
Veralto Corp
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,694 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Tax withholding · Disposed 3,305 · Balance 53,694 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 6, 2019 01:16 UTC | Chemours Co CC · Entity 4420 | GrantStock Option (Right to Buy) · Derivative | 17,830 | $0.00 Strike: $21.96 | $0.00 |
DisclosureSEC source: 0001627223-19-000036 · primary_doc.xml · derivative · entry 1 Ralhan Sameer · CIK 0001778813 · SVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,830 Underlying: Common Stock · 17,830 shares Expires 2029-06-03 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.